These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19379452)

  • 21. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
    Thohan V; Torre-Amione G; Koerner MM
    Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.
    Little WC; Zile MR; Kitzman DW; Hundley WG; O'Brien TX; Degroof RC
    J Card Fail; 2005 Apr; 11(3):191-5. PubMed ID: 15812746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doppler evaluations of left ventricular diastolic filling and pulmonary wedge pressure provide similar prognostic information in patients with systolic dysfunction after myocardial infarction.
    Pozzoli M; Capomolla S; Sanarico M; Pinna G; Cobelli F; Tavazzi L
    Am Heart J; 1995 Apr; 129(4):716-25. PubMed ID: 7900623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.
    Cicoira M; Zanolla L; Rossi A; Golia G; Franceschini L; Brighetti G; Marino P; Zardini P
    J Am Coll Cardiol; 2002 Jul; 40(2):304-10. PubMed ID: 12106936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
    Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
    JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.
    McDiarmid AK; Swoboda PP; Erhayiem B; Bounford KA; Bijsterveld P; Tyndall K; Fent GJ; Garg P; Dobson LE; Musa TA; Foley JRJ; Witte KK; Kearney MT; Greenwood JP; Plein S
    J Am Heart Assoc; 2020 Jan; 9(1):e011521. PubMed ID: 31852424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
    Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
    JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; Marwick TH
    Heart; 2013 Mar; 99(5):320-6. PubMed ID: 23343682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
    Sperry BW; Hanna M; Shah SJ; Jaber WA; Spertus JA
    JACC Heart Fail; 2021 Nov; 9(11):795-802. PubMed ID: 34509404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients.
    Gu J; Fan YQ; Han ZH; Fan L; Bian L; Zhang HL; Xu ZJ; Yin ZF; Xie YS; Zhang JF; Wang CQ
    Int J Cardiol; 2016 Oct; 220():56-60. PubMed ID: 27372043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of the evaluation of left ventricular diastolic function changes during stress echocardiography in predicting exercise capacity in patients with ischemic heart failure.
    Podolec P; Rubís P; Tomkiewicz-Pajak L; Kopeć G; Tracz W
    J Am Soc Echocardiogr; 2008 Jul; 21(7):834-40. PubMed ID: 18222643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Santos AB; Roca GQ; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Fang JC; Zile MR; Pitt B; Solomon SD; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002763. PubMed ID: 27056882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
    Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
    Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
    Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
    Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
    Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand IS; Rouleau JL; Desai AS; Lewis EF; Vaduganathan M; Wang SY; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2019 Jul; 12(7):e006125. PubMed ID: 31220936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.